Kinetic characterization of 4,4′-biphenylsulfonamides as selective non-zinc binding MMP inhibitors

References

• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinas: regulators of the tumor microenvironment. Cell 2010;141:52–67
   PubMed Web of Science ®Google Scholar
• Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61–75
   PubMed Web of Science ®Google Scholar
• Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999;99:2735–76
   PubMed Web of Science ®Google Scholar
• Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19:6642–50
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387–92
   PubMed Web of Science ®Google Scholar
• Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 2014;13:904–27
   PubMed Web of Science ®Google Scholar
• Chen JM, Nelson FC, Levin JI, Mobilio D, Moy FJ, Nilakantan R, et al. Structure-based design of a novel, potent and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. J Am Chem Soc 2000; 122:9648–54
   Web of Science ®Google Scholar
• Morales R, Perrier S, Florent JM, et al. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J Mol Biol 2004;341:1063–76
   PubMed Web of Science ®Google Scholar
• Dublanchet AC, Ducrot P, Andrianjara C, et al. Structure based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorg Med Chem Lett 2005;15:3787–90
   PubMed Web of Science ®Google Scholar
• Engel CK, Pirard B, Schimanski S, et al. Structural basis for the highly selective inhibition of MMP-13. Chem Biol 2005;12:181–9
   PubMed Web of Science ®Google Scholar
• Gooljarsingh LT, Lakdawala A, Coppo F, et al. Characterization of an exosite binding inhibitor of matrix metalloprotease 13. Protein Sci 2008;17:66–71
   PubMed Web of Science ®Google Scholar
• Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007;282:27781–91
   PubMed Web of Science ®Google Scholar
• Li JJ, Nahra J, Johnson AR, et al. Quinazolinones and pyrido-[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloprotease-13 inhibitors for the treatment of osteoarthritis. J Med Chem 2008;51:835–41
   PubMed Web of Science ®Google Scholar
• Sasanelli R, Boccarelli A, Giordano D, et al. Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl) methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12. J Med Chem 2007;50:3434–41
   PubMed Web of Science ®Google Scholar
• Udi Y, Fragai M, Grossman M, et al. Unraveling hidden regulatory sites in structurally homologous metalloproteases. J Mol Biol 2013;425:2330–46
   PubMed Web of Science ®Google Scholar
• Dufour A, Zucker S, Sampson NS, et al. Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem 2010;285:35944–56
   PubMed Web of Science ®Google Scholar
• Dufour A, Sampson NS, Li J, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res 2011;71:4977–88
   PubMed Web of Science ®Google Scholar
• Remacle AG, Golubkov VS, Shiryaev SA, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res 2012;72:2339–49
   PubMed Web of Science ®Google Scholar
• Overall CM, Kleifeld O. Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227–39
   PubMed Web of Science ®Google Scholar
• Kudo Y, Iizuka S, Yoshida M, et al. Matrix metalloproteinase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis. J Biol Chem 2012;287:38716–28
   PubMed Web of Science ®Google Scholar
• Shah M, Huang D, Blick T, et al. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. PLoS One 2012;7:e29615
   Google Scholar
• La Regina G, Coluccia A, Famiglini V, et al. Synthesis and biological evaluation of 4,4′-biphenylylsulfonamides as a new class of potent and selective carbonic anhydrase XIV inhibitors. ACS Med Chem Lett
   Google Scholar
• Yonetani T, Theorell H. Studies on liver alcohol hydrogenase complexes. 3. Multiple inhibition kinetics in the presence of two competitive inhibitors. Arch Biochem Biophys 1964;106:243–51
   PubMed Web of Science ®Google Scholar
• Dixon M, Webb EC, Thorne CJR, Tipton KF. Enzymes. 3rd ed. London: Longmans, Green & Co; 1979
   Google Scholar
• Nuti E, Panelli L, Casalini F, et al. Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloprotease-12 inhibitors. J Med Chem 2009;52:6347–61
   PubMed Web of Science ®Google Scholar
• Neumann U, Kubota H, Frei K, et al. Characterization of Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme. Anal Biochem 2004;328:166–73
   PubMed Web of Science ®Google Scholar
• Cheng YC, Prusoff, WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) or an enzymatic reaction. Biochem Pharm 1973;22:3099–108
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77
   PubMed Web of Science ®Google Scholar
• Marques SM, Nuti E, Rossello A, et al. Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates. J Med Chem 2008;51:7968–79
   PubMed Web of Science ®Google Scholar
• Esteves MA, Ortet O, Capelo A, et al. New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors. Bioorg Med Chem Lett 2010;20:3623–7
   PubMed Web of Science ®Google Scholar
• Westley AM, Westley J. Enzyme inhibition in open systems. Superiority of uncompetitive agents. J Biol Chem 1996;271:5347–52
   PubMed Web of Science ®Google Scholar
• De Savi C, Morley AD, Ting A, et al. Selective non-zinc binding inhibitors of MMP13. Bioorg Med Chem Lett 2011;21:4215–9
   PubMed Web of Science ®Google Scholar